EpiPen Price History and Mylan’s Market Dominance
EpiPen prices rose sharply over the past decade, with a two-pack list price climbing from around 100 dollars in 2009 to over 600 dollars by 2016, a trend widely described as epipen price gouging. Mylan controlled roughly 90 percent of the U.S. epinephrine auto-injector market during that period, giving it outsized pricing power while competitors struggled to gain traction read more.
In 2016, Mylan’s CEO Heather Bresch saw her compensation rise as the company faced bipartisan hearings on epipen price gouging, with lawmakers questioning why the device’s list price increased nearly 400 percent over seven years. Mylan later settled with the U.S. Department of Justice for 465 million dollars over allegations that it misclassified EpiPen as a generic to reduce Medicaid rebates, a resolution that did not directly admit wrongdoing read more.
Competitor Failures and Regulatory Barriers
Teva’s Generic Attempt and FDA Delays
Teva received FDA approval for a generic epinephrine auto-injector in 2018, but the product faced supply constraints and limited insurance formulary placement, allowing Mylan to maintain dominant pricing through most of the 2010s. The slow rollout of alternatives contributed to accusations of epipen price gouging, as patients and insurers continued to pay list prices far above the device’s manufacturing cost.
Sandoz and Other Generic Entrants
Sandoz launched a generic version in 2019, yet pharmacy benefit managers and insurers often steered patients toward Mylan’s product through rebate structures and formulary preferences, limiting the competitive pressure that could have lowered net prices. These dynamics kept EpiPen at the center of epipen price gouging debates even after generic options became available read more.
Recent Developments, Settlements, and Current Pricing
Mylan’s Rebranding and Viatris Transition
Mylan merged with Upjohn in 2020 to form Viatris, which inherited the EpiPen franchise and continued to face scrutiny over legacy pricing practices tied to epipen price gouging. Viatris introduced authorized generics and rebate programs aimed at lowering out-of-pocket costs, though list prices remained high relative to the device’s manufacturing expense.
Ongoing Legal and Congressional Oversight
Congressional investigations and state-level lawsuits pressed companies on transparency around epinephrine auto-injector pricing, with several states exploring anti-price-gouging statutes for essential medical devices. The EpiPen case remains a reference point in debates over drug pricing reform, pharmacy benefit manager practices, and the role of government in capping out-of-pocket costs for life-saving devices